Target intelligence / Profile preview

Dimethyl sulfoxide reductase (DMSO reductase)

Target
DMSO reductase
Molecular classification
Enzyme, Oxidoreductase, Molybdenum enzyme
01

Overview

Dimethyl sulfoxide reductase (DMSO reductase, DMSOR) is a molybdenum-containing enzyme found predominantly in bacteria and archaea[1][3][7]. It catalyzes the reduction of dimethyl sulfoxide (DMSO) to dimethyl sulfide (DMS) during anaerobic respiration, where DMSO is used as a terminal electron acceptor[1][6][8]. DMSO reductase has a highly conserved active site with molybdenum coordinated by two molybdopterin guanine dinucleotide cofactors and, depending on its subclass, an additional amino acid ligand (serine, cysteine, or aspartate)[1][3][7]. It plays a significant ecological role in the global sulfur cycle and can influence atmospheric processes by contributing to DMS release, which affects cloud formation and climate regulation[3][7]. While not a therapeutic target for drugs in human medicine, its metabolic activity is essential in microbial biochemistry and has potential utility in bioremediation and synthetic biocatalysis[2][7]. DMSO reductase enzymes are phylogenetically widespread in prokaryotes and represent one of the largest families of prokaryotic molybdoenzymes[7].

Other names
Dimethylsulfoxide reductaseDMSO reductaseDMSOR
02

Mechanism of action

Catalyzes the two-electron reduction of dimethyl sulfoxide (DMSO) to dimethyl sulfide (DMS) at a molybdenum active center; Acts as a terminal electron acceptor in bacterial anaerobic metabolism

03

Biological functions

Anaerobic respirationTerminal electron transferRedox reactions (specifically reduction of sulfoxides and N-oxides)Oxygen atom transferParticipation in sulfur cycle and global sulfur fluxIn some prokaryotes, nitrogen cycle involvement
04

Disease associations

Infection (important in certain pathogen metabolism)Other (no established role in human diseases, potential bioremediation applications)
05

Safety considerations

Not used as a direct drug target; no major therapeutic challenges known; potential concern for toxic byproducts (DMS) in environmental contexts
06

Interacting drugs

None established for clinical use. Some inhibitors known in research, but no approved drugs.
07

Biomarkers

None established for clinical patient selection; activity may be used as a microbial biomarker in environmental studies

Beyond the preview

Go deeper on Dimethyl sulfoxide reductase (DMSO reductase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dimethyl sulfoxide reductase (DMSO reductase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call